CervoMed Updates Stakeholders on Clinical and Financial Status
CervoMed Is Maintained at Buy by Canaccord Genuity
CervoMed Is Maintained at Buy by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the CervOmed (CRVO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $50.00 to $65.00.
Canadian Investment Banking Group: Maintaining the CervOmed (CRVO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $50.00 to $65.00.
Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed with a Buy and raises the price target from $50 to $65.
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
CervoMed Shares Operational and Financial Insights Online
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
CervoMed GAAP EPS of -$0.82 Beats by $1.23, Revenue of $7.14M Beats by $3.09M
CervoMed 2023 Loss $2.2M >CRVO
CervoMed 2023 Loss $2.2M >CRVO
Press Release: CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates - Announced private placement of up to $149.4 million led by RA Capital Management with participati
Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will
CervoMed Shares Rise 20% After Private Placement Pricing
By Chris Wack CervoMed shares rose after the company entered into a definitive securities purchase agreement for a private placement to sell 2.5 million units. The neurological disorder-focused comp
CervoMed Prices $50 Million Equity Sale to Private Investors
CervoMed (CRVO) on Thursday priced a private sale of around 2.5 million units that are each composed of a share of common stock and a pre-funded warrant to purchase another share for $19.745. The priv
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied to exercise of
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersYield10 Bioscience (NASDAQ:YTEN) shares moved upwards by 71.5% to $0.42 during Thursday's regular session. The market value of their outstanding shares is at $4.9 million. Monogram Orthopaedics
CervoMed Inc. (NASDAQ:CRVO) Surges 53%; Retail Investors Who Own 48% Shares Profited Along With Insiders
Key Insights CervoMed's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 6 shareholders own 50% of the company
CervoMed Updates Investors on Clinical and Financial Health
CervoMed Announces Presentation of Biomarker Data From the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD 2024
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed by CDR Sum of Boxes
CervoMed to Participate in the BIO CEO and Investor Conference
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company
No Data